We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

GSK is delivering consistent financial performance ... and six with national reimbursement programs. More rollouts across Europe and international will come in 2025. For Shingrix, year-to-date ...

European stocks closed weak on Wednesday, with investors reacting to a slew of economic data from the region, the UK budget, and ...

European markets are heading for a negative open Wednesday, as investors await the latest growth data from the region and ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

European stocks closed broadly higher on Tuesday with investors largely making cautious moves, digesting mixed earnings updates and ...

Get global perspectives and insights from CEOs on the biggest stories in business. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...